Ronald Emkey - Concepedia

Author

Ronald Emkey

Also Known As

Abanoub Gabra, J. A. Stakkestad, M. A. Levine, R Emkey, R. Emkey, R.D. Emkey, Ronald D Emkey, Ronald D. Emkey, Ronald Emkey

Publications

7.5K

Citations

H-Index

Concepts

All Affiliations

Radiant Research (United States)Merck & Co., Inc., Rahway, NJ, USA (United States)Reading Hospital Hôpital Edouard Herriot Altoona Arthritis and Osteoporosis Center

About

Ronald Emkey is an author at Radiant Research (United States) specializing in medicine, bone health, and osteoporosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	2.2K
2	Health Sciences	2	2	450
3	Arts	1	1	54
4	Clinical Nutrition	1	1	40
5	Comparative Literature	1	1	54

Ronald Emkey

Publications

6.5K

Citations

H-Index

Page 1

	Year	Citations
Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women Henry G. Bone, David Hosking, Jean‐Pierre Devogelaer, New England Journal of Medicine	2004	1.3K
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis Kenneth G. Saag, Ronald Emkey, Thomas J. Schnitzer, New England Journal of Medicine	1998	1.3K
Risedronate therapy prevents corticosteroid-induced bone loss : A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Stanley Cohen, Robert M. Levy, Michael Keller, Arthritis & Rheumatism	1999	615
Skeletal Benefits of Alendronate: 7-Year Treatment of Postmenopausal Osteoporotic Women<sup>1</sup> Richard P. Tonino, Pierre J. Meunier, Ronald Emkey, The Journal of Clinical Endocrinology & Metabolism GynecologyPharmacotherapyOsteoporosisOrthopaedic SurgeryBone Disease	2000	337
The Efficacy and Tolerability of Risedronate Once a week for the Treatment of Postmenopausal Osteoporosis Jacques P. Brown, David L. Kendler, Michael R. McClung, Calcified Tissue International Bone DiseaseBone HealthRisedronate OnceMedicineOrthopaedics	2002	334
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study Reginster Jy, S. Adámi, Péter L. Lakatos, Annals of the Rheumatic Diseases Bone DiseaseOnce-monthly Oral IbandronateBone HealthMobile StudyOrthopaedics	2005	329
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Thomas J. Schnitzer, Henry G. Bone, G Crepaldi, PubMed Bone DiseaseBone HealthAlendronate 10Orthopaedic SurgeryAlendronate 70	2000	299
Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis Joseph Tucci, Richard P. Tonino, Ronald Emkey, The American Journal of Medicine Bone DiseaseBone HealthGynecologyMenopauseOsteoporosis	1996	222
Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study Kenneth G. Saag, Rachel B. Wagman, Piet Geusens, The Lancet Diabetes & Endocrinology Bone DiseaseBone HealthGlucocorticoid-induced OsteoporosisDenosumab Versus RisedronateNon-inferiority Study	2018	191
Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO) Ronald Emkey, William Koltun, Kathleen Beusterien, Current Medical Research and Opinion	2005	170

Page 1